ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS
NCT ID: NCT03822988
Last Updated: 2019-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2019-01-21
2019-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic.
Seconds endpoints are :
For patients against or not planning to write it, understand their reasons
Estimate the proportion of patients requesting information and understand how they would like to receive it.
Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessments and Recommendations for the Implementation of Advance Directives in Oncology
NCT02634632
Which Health-care Professional(s) to Talk About Advance Care Planning ?
NCT06376799
Study of the Life Stories of Patients Making a Request for Euthanasia, in the Context of Advanced Cancer.
NCT05884788
Feasibility of an Advance Care Planning Intervention
NCT06149312
An Observational Study of the Prevalence of Patients Requiring Palliative Care in French Anti-cancer Centers.
NCT02479061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients accepting to answer to the survey
patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
no intervention, only complete a survey
we will ask patients to answer to a survey
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention, only complete a survey
we will ask patients to answer to a survey
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
With one of the diagnoses below:
* Melanoma
* Skin lymphoma
* Meckel Carcinoma
* localy advanced or metastatic Basal cell carcinoma or squamous cell carcinoma
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
anne-claire bursztejn
Role: PRINCIPAL_INVESTIGATOR
CHRU Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU Nancy-Brabois hospital
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSS-2018/PADAONCODERM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.